Effects of Levosimendan on Cardiac Function After TAVR in Patients With Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 112 participants.

Also called NCT06196177

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 112 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06196177
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06196177. Randomized; single masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Levosimendan on Cardiac Function After TAVR in Patients With Heart Failure
Condition
Heart Failure
Condition
Aortic Stenosis, Severe
Intervention (Drug)
Levosimontane injection
Lead sponsor
Qilu Hospital of Shandong University (class: other)

Record details

Record id
cardio:ct-nct06196177
Content hash
5eec686319bee4feafe3a748874e53c6b22024633bcf61653bb6ffa23c52116f